BioChem C785 - WGU - Module 2 - all questions graded A

BioChem C785 - WGU - Module 2 - all questions graded A Deedra's dad has Alzheimer's Disease (AD) which is caused by a change in protein structure True Alzheimer's disease is caused by aggregation of the Amyloid beta peptide and tangle formation by the tau protein. What kinds of amino acids are likely to drive the formation of these protein aggregates? hydrophobic After learning about Alzheimer's disease and one of the drugs used in its treatment, what other drug design strategies could you use to offer treatment for AD? 1. Drugs that break up the amyloid plaques 2. Drugs that block the production of amyloid beta peptide 3. drugs that inhibits the aggregation of protein structures A substrate binds to an enzyme at a specific site is referred to as an active site You are in charge of designing a drug that inhibits the activity of a specific enzyme. An important criteria for the drug selection is to ensure that the drug is directly in competition with the original substrate when binding to the active site of the enzyme. What inhibitor would be an ideal choice? A competitive inhibitorThese factors can affect the protein folding and activity of an enzyme: 1. pH 2. Heat 3. Reducing agents One way a cell can avoid overproduction of a molecule is by using a particular type of inhibition in which the molecule itself acts as an inhibitor for an enzyme in its production pathway. This type of regulation is known as feedback inhibition True What type of enzyme adds a phosphate to another molecule? Kinase What are possible effects that phosphorylation/dephosphorylation can have on the activity of an enzyme? 1. turn the enzyme on 2. turn the enzyme o